Table 5.
Variable-Adjusted ORs and 95% Confidence Intervals of Baseline Serum CRP Concentrations and Pancreatic Cancer Stratified by Median Age in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, and Both Cohorts Combined
| ATBC | Quintile of Serum CRP Concentration, ng/ml* | ||||||
|---|---|---|---|---|---|---|---|
| <58 years old | Q1 | Q2 | Q3 | Q4 | Q5 | Ptrend | Continuous |
| C-Reactive Protein | ≤1.97 | >1.97 and ≤4.06 | >4.06 and ≤7.42 | >7.42 and ≤14.05 | >14.05 | ||
| Cases/Controls, n | 35/46 | 29/49 | 32/52 | 28/43 | 17/46 | ||
| Crude OR (95% CI)† | 1.00 (reference) | 0.77 (0.41–1.46) | 0.80 (0.43–1.49) | 0.85 (0.44–1.62) | 0.49 (0.24–0.99) | 0.04 | 0.90 (0.82–1.00) |
| Smoking-adjusted OR (95% CI)‡ | 1.00 (reference) | 0.76 (0.40–1.44) | 0.76 (0.40–1.43) | 0.82 (0.43–1.59) | 0.48 (0.24–0.99) | 0.05 | 0.90 (0.82–1.00) |
| ≥58 years old | |||||||
| Cases/Controls, n | 29/56 | 42/53 | 49/50 | 22/60 | 28/55 | ||
| Crude OR (95% CI)† | 1.00 (reference) | 1.53 (0.83–2.79) | 1.91 (1.05–3.48) | 0.72 (0.37–1.41) | 0.99 (0.52–1.87) | 0.12 | 0.95 (0.90–1.01) |
| Smoking-adjusted OR (95% CI)‡ | 1.00 (reference) | 1.46 (0.79–2.68) | 1.80 (0.98–3.30) | 0.70 (0.36–1.36) | 0.93 (0.49–1.78) | 0.09 | 0.95 (0.89–1.01) |
| PLCO | Quintile of Serum CRP Concentration, ng/ml* | ||||||
| <66 years old | Q1 | Q2 | Q3 | Q4 | Q5 | Ptrend | Continuous |
| C-Reactive Protein | ≤1.52 | >1.52 and ≤2.96 | >2.96 and ≤5.98 | >5.98 and ≤10.48 | >10.48 | ||
| Cases/Controls, n | 24/38 | 13/40 | 16/30 | 17/31 | 20/35 | ||
| Crude OR (95% CI)§ | 1.00 (reference) | 0.66 (0.21–2.11) | 0.98 (0.36–2.68) | 1.00 (0.35–2.85) | 0.95 (0.37–2.45) | 0.39 | 0.97 (0.90–1.04) |
| Smoking-adjusted OR (95% CI)‖ | 1.00 (reference) | 0.53 (0.15–1.80) | 1.03 (0.34–3.17) | 0.93 (0.31–2.80) | 0.65 (0.23–1.84) | 0.26 | 0.95 (0.86–1.04) |
| ≥66 years old | |||||||
| Cases/Controls, n | 9/35 | 12/32 | 23/43 | 28/41 | 20/37 | ||
| Crude OR (95% CI)§ | 1.00 (reference) | 0.93 (0.25–3.49) | 1.71 (0.62–4.69) | 2.85 (1.01–8.05) | 2.06 (0.68–6.24) | 0.46 | 1.02 (0.97–1.08) |
| Smoking-adjusted OR (95% CI)‖ | 1.00 (reference) | 0.73 (0.18–3.01) | 1.68 (0.60–4.67) | 2.44 (0.81–7.33) | 1.43 (0.43–4.78) | 0.77 | 1.01 (0.95–1.08) |
| Combined | Quintile of Serum CRP Concentration, ng/ml* | ||||||
| Younger individuals** | Q1 | Q2 | Q3 | Q4 | Q5 | Ptrend | Continuous |
| C-Reactive Protein | ≤1.67 | >1.67 and ≤3.64 | >3.64 and ≤6.79 | >6.79 and ≤12.59 | >12.59 | ||
| Cases/Controls, n | 59/84 | 42/89 | 48/82 | 45/74 | 37/81 | ||
| Crude OR (95% CI)§ | 1.00 (reference) | 0.67 (0.41–1.10) | 0.82 (0.51–1.34) | 0.86 (0.52–1.42) | 0.65 (0.39–1.09) | 0.13 | 0.96 (0.92–1.01) |
| Smoking-adjusted OR (95% CI)‖ | 1.00 (reference) | 0.66 (0.40–1.09) | 0.83 (0.51–1.36) | 0.81 (0.49–1.35) | 0.60 (0.36–1.02) | 0.08 | 0.95 (0.90–1.01) |
| Older individuals†† | |||||||
| Cases/Controls, n | 38/91 | 54/85 | 72/93 | 50/101 | 48/92 | ||
| Crude OR (95% CI)§ | 1.00 (reference) | 1.51 (0.91–2.52) | 1.91 (1.17–3.12) | 1.25 (0.75–2.08) | 1.29 (0.77–2.16) | 0.82 | 0.98 (0.95–1.02) |
| Smoking-adjusted OR (95% CI)‖ | 1.00 (reference) | 1.49 (0.89–2.49) | 1.89 (1.15–3.10) | 1.19 (0.71–2.00) | 1.19 (0.71–2.02) | 0.24 | 0.98 (0.94–1.02) |
| Combined cohort-specific cutpoints‡‡ | Quintile of Serum CRP Concentration, ng/ml* | ||||||
| Younger individuals** | Q1 | Q2 | Q3 | Q4 | Q5 | Ptrend | |
| Cases/Controls, n | 59/84 | 42/89 | 48/82 | 45/74 | 37/81 | ||
| Crude OR (95% CI)§ | 1.00 (reference) | 0.68 (0.38–1.22) | 0.77 (0.45–1.31) | 0.87 (0.51–1.49) | 0.79 (0.44–1.40) | 0.28 | |
| Smoking-adjusted OR (95% CI)‖ | 1.00 (reference) | 0.72 (0.40–1.31) | 0.79 (0.46–1.37) | 0.86 (0.50–1.48) | 0.81 (0.45–1.47) | 0.17 | |
| Older individuals†† | |||||||
| Cases/Controls, n | 38/91 | 54/85 | 72/93 | 50/101 | 48/92 | ||
| Crude OR (95% CI)§ | 1.00 (reference) | 1.32 (0.78–2.26) | 1.98 (1.20–3.28) | 1.32 (0.79–2.23) | 1.25 (0.72–2.17) | 0.68 | |
| Smoking-adjusted OR (95% CI)‖ | 1.00 (reference) | 1.39 (0.80–2.41) | 1.89 (1.13–3.15) | 1.19 (0.69–2.04) | 1.28 (0.73–2.27) | 0.92 | |
Interaction by age not significant for ATBC and PLCO, but significant in combined analyses (P=0.91, P=0.05, and P=0.02, respectively)
Crude OR adjusted for matching variables (age, date of blood draw, follow-up time)
Multivariable model additionally adjusted for smoking intensity and smoking duration
Crude OR adjusted for matching variables (age, race, sex, date of blood draw)
Adjusted for smoking (never, former quit ≥ 15 years ago, former quit < 15 years ago, current)
Combined subjects <58 years old from ATBC and those <66 years old from PLCO
Combined subjects ≥58 years old from ATBC and those ≥66 years old from PLCO
Cohort specific cut-points based on CRP concentrations based on ATBC and PLCO controls separately as defined above